Idera Pharmaceuticals IDRA today announced that 48% of
patients with moderate-to-severe plaque psoriasis (12 of 25) treated
with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7
and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI)
scores of 35% to 90% from baseline at the completion of a randomized,
double-blind, placebo-controlled Phase 2a clinical trial of two dose
levels of IMO-3100 administered for four weeks, with a four-week
follow-up period. None of the 12 placebo-treated patients had
improvement in this range; this difference was statistically significant
(p<0.005). The Company believes the results of this trial provide
clinical proof-of-concept for the mechanism of action of selective TLR
inhibition in patients with psoriasis and potentially other autoimmune
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in